Gout Archives - Page 9 of 9 - MPR


FDA halts marketing of unapproved colchicine

The FDA has informed companies that manufacture, distribute, and/or market unapproved single-ingredient oral colchicine that they are expected to stop manufacturing single-ingredient oral colchicine within 45 days and must stop shipping this unapproved product in interstate commerce within 90 days.

KRYSTEXXA (pegloticase) 8mg/1mL injection by Savient

Krystexxa approved for chronic gout

The FDA has approved Krystexxa (pegloticase injection, from Savient), a PEGylated uric acid specific enzyme, for the treatment of chronic gout in adult patients refractory to conventional therapy.